1H-苯并[D] 氮杂卓-2,4(3H,5H)-二酮 | 2184-00-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 中文名称: 1H-苯并[D] 氮杂卓-2,4(3H,5H)-二酮
• 中文别名: 1H-苯并[D]氮杂卓-2,4(3H,5H)-二酮
• 英文名称: 1,5-dihydro-benzo[d]azepine-2,4-dione
• 英文别名: 1,5-dihydro-benz[d]azepine-2,4-dione；1,5-Dihydro-benz[d]azepin-2,4-dion；1,3,4,5-tetrahydro-2H-3-benzazepin-2,4-dione；1,5-dihydro-benzo[d]azepine-2,4-dione；2,4-Dioxo-2,3,4,5-tetrahydro-1H-3-benzazepin；o-Phenylendiacetimid；1H-3-benzazepine-2,4(3H,5H)-dione；1,5-dihydro-3-benzazepine-2,4-dione
• CAS: 2184-00-1
• 化学式: C₁₀H₉NO₂
• mdl: MFCD01632506
• 分子量: 175.187
• InChiKey: VAZUVSAEURIXET-UHFFFAOYSA-N

物化性质

• 熔点：
  191-192 °C
• 沸点：
  399.0±31.0 °C(Predicted)
• 密度：
  1.224±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  46.2
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2925190090

反应信息

• 作为反应物：
  描述：

  1H-苯并[D] 氮杂卓-2,4(3H,5H)-二酮 在 dimethyl sulfide borane 、 盐酸 作用下， 以 甲苯 、 1,4-二氧六环 为溶剂， 以52.7 %的产率得到2,3,4,5-四氢-1H-苯并[D]氮杂卓(盐酸盐)
  参考文献：
  名称：

  [EN] ARGININE METHYLTRANSFERASE INHIBITOR AND USE THEREOF
  [FR] INHIBITEUR DE L'ARGININE MÉTHYLTRANSFÉRASE ET SON UTILISATION
  [ZH] 一类精氨酸甲基转移酶抑制剂及其用途

  摘要：

  本发明提供了一类精氨酸甲基转移酶抑制剂及其用途，具体地，本发明提供了一类可以用作I型PRMT抑制剂的化合物、其制备方法以及在相关疾病治疗中的应用。所述的化合物具有式I所示的结构。

  公开号：

  WO2022242696A1
• 作为产物：
  描述：

  4-bromo-1H-benzo[d]azepin-2-ylamine 生成 1H-苯并[D] 氮杂卓-2,4(3H,5H)-二酮
  参考文献：
  名称：

  摘要：

  DOI：

文献信息

• (2H)-3-benzazepin-2-ones, their pharmaceutical compositions and their
  申请人：Dr. Karl Tomae, GmbH

  公开号：US04737495A1

  公开（公告）日：1988-04-12

  The invention relates to new heteroaromatic amine derivatives of formula ##STR1## wherein A represents a --CH.sub.2 --CH.sub.2 --, --CH.dbd.CH--or ##STR2## group and B represents a methylene, carbonyl or thiocarbonyl group or A represents a --CO--CO or ##STR3## group and B represents a methylene group, in which the carbon atom marked x is linked to the phenyl nucleus, E represents a straight-chained alkylene group optionally substituted by an alkyl group, G represents a straight-chained alkylene group optionally substituted by an alkyl group, R.sub.1 represents a hydrogen, fluorine, chlorine or bromine atom, a trifluoromethyl, nitro, amino, alkylamino, dialkylamino, alkyl, alkylmercapto, hydroxy, alkoxy or phenylalkoxy group, R.sub.2 represents a hydrogen, chlorine or bromine atom or a hydroxy, alkoxy, phenylalkoxy or alkyl group or R.sub.1 and R.sub.2 together represent an alkylenedioxy group, R.sub.3 represents a hydrogen atom, an alkenyl group, an alkyl or phenylalkyl group, and Het represents a 5- or 6-membered heteroaromtic ring bonded via a carbon or nitrogen atom, which contains an oxygen, sulphur or nitrogen atom, two nitrogen atoms or a nitrogen atom and an oxygen or sulphur atom, and onto which additionally a phenyl ring can be condensed, in which case the bond can also be via the phenyl nucleus, or an imidazo[1,2-a]pyridyl group wherein the carbon structure of the above-mentioned groups can be substituted by a methylenedioxy or ethylenedioxy group or can be mono- or disubstituted by a halogen atom or an alkyl, hydroxy, alkoxy, phenylalkoxy, phenyl, dimethoxyphenyl, nitro, amino, acetylamino, carbamoylamino, N-alkyl-carbamoylamino, hydroxymethyl, mercapto, alkylmercapto, alkylsulphinyl, alkylsulphonyl, alkylsulphonyloxy, alkylsulphonylamino, alkoxycarbonylmethoxy, carboxymethoxy or alkoxymethyl group, and at the same time any imino group present in the above-mentioned heteroaromatic groups can be substituted by an alkyl, phenylalkyl or phenyl group, the N-oxides and the acid addition salts thereof with inorganic or organic acids, which have valuable pharmacological properties, particularly the effect of lowering heart rate and oxygen requirement of the heart. They can be used to treat sinus tachycardia or ischaemic heart disease.

  本发明涉及新的杂芳胺衍生物，其化学式为##STR1##其中A代表--CH.sub.2 --CH.sub.2 --，--CH.dbd.CH--或##STR2##基团，B代表一个亚甲基、羰基或硫代羰基基团，或者A代表--CO--CO或##STR3##基团，B代表一个亚甲基基团，其中标有x的碳原子与苯环相连，E代表一条直链烷基基团，该基团可选择由烷基基团取代，G代表一条直链烷基基团，该基团可选择由烷基基团取代，R.sub.1代表氢、氟、氯或溴原子，三氟甲基、硝基、氨基、烷基氨基、二烷基氨基、烷基、烷基硫醇基、羟基、烷氧基或苯基氧基基团，R.sub.2代表氢、氯或溴原子或羟基、烷氧基、苯基氧基或烷基基团，或者R.sub.1和R.sub.2一起代表烷二氧基基团，R.sub.3代表氢原子、烯基基团、烷基或苯基烷基基团，Het代表通过碳或氮原子键合的含有氧、硫或氮原子、两个氮原子或一个氮原子和一个氧或硫原子的5-或6-成员杂芳环，其上还可以附加一个苯环，并且在这种情况下，键合也可以通过苯环核心进行，或者是一种咪唑并[1,2-a]吡啶基团，在上述基团的碳结构可以被甲二氧基或乙二氧基基团取代，或者可以被卤原子或烷基、羟基、烷氧基、苯基氧基、苯基、二甲氧基苯基、硝基、氨基、乙酰氨基、氨基甲酰氨基、N-烷基-氨基甲酰氨基、羟甲基、硫醇基、烷基硫醇基、烷基磺酰基、烷基磺酰氧基、烷基磺酰氨基、烷氧羰基甲氧基、羧基甲氧基或烷氧甲基基团单取代或双取代，同时上述杂芳基团中存在的任何亚胺基团可以被烷基、苯基烷基或苯基取代，以及它们的N-氧化物和与无机或有机酸形成的酸加合盐，具有有价值的药理性能，特别是降低心率和心脏氧需求的作用。它们可用于治疗窦性心动过速或缺血性心脏病。
• Novel indole derivatives and pharmaceutical compositions containing same
  申请人：Dr. Karl Thomae GmbH

  公开号：US04616011A1

  公开（公告）日：1986-10-07

  This invention relates to novel indole derivatives of the formula ##STR1## wherein A represents a --CH.sub.2 --CH.sub.2 --, --CH.dbd.CH--, ##STR2## group and B represents a methylene, carbonyl, or thiocarbonyl group or A represents a --CO--CO-- or ##STR3## group and B represents a methylene group, E represents an alkylene group or a 2-hydroxy-n-propylene, 2-hydroxy-n-butylene, or 3-hydroxy-n-butylene group, G represents an alkylene group, R.sub.1 represents a hydrogen, chlorine, or bromine atom or a trifluoromethyl, nitro, amino, alkylamino, dialkylamino, alkyl, hydroxyl, alkoxy, or phenylalkoxy group, R.sub.2 represents a hydrogen, chlorine, or bromine atom or a hydroxyl, alkoxy, phenylalkoxy, or alkyl group or R.sub.1 and R.sub.2 together represent an alkylenedioxy group, R.sub.3 represents a hydrogen, chlorine, or bromine atom or an alkyl group, R.sub.4 represents a hydrogen atom or an alkyl or phenylalkyl group, R.sub.5 represents a hydrogen, fluorine, chlorine, or bromine atom or an alkyl, hydroxyl, alkoxy, or phenylalkoxy group, R.sub.6 represents a hydrogen atom or an alkoxy group, and R.sub.7 represents a hydrogen atom or an alkenyl, alkyl or phenylalkyl group, and the acid additional salts thereof. These compounds, which may be obtained by use of known methods, have valuable pharmacological properties, particularly a heart rate-lowering activity.

  本发明涉及一种新的吲哚衍生物，其化学式为##STR1## 其中A代表--CH.sub.2 --CH.sub.2 --、--CH.dbd.CH--、##STR2##基团，B代表甲基、羰基或硫代羰基基团，或A代表--CO--CO--或##STR3##基团，B代表亚甲基基团，E代表烷基基团或2-羟基-n-丙烷基、2-羟基-n-丁烷基或3-羟基-n-丁烷基基团，G代表烷基基团，R.sub.1代表氢、氯或溴原子或三氟甲基、硝基、氨基、烷基氨基、二烷基氨基、烷基、羟基、烷氧基或苯基烷氧基基团，R.sub.2代表氢、氯或溴原子或羟基、烷氧基、苯基烷氧基或烷基基团或R.sub.1和R.sub.2一起代表烷基二氧基基团，R.sub.3代表氢、氯或溴原子或烷基基团，R.sub.4代表氢原子或烷基或苯基烷基基团，R.sub.5代表氢、氟、氯或溴原子或烷基、羟基、烷氧基或苯基烷氧基基团，R.sub.6代表氢原子或烷氧基，R.sub.7代表氢原子或烯丙基、烷基或苯基烷基基团，以及它们的酸性附加盐。这些化合物可以通过已知方法获得，具有有价值的药理学性质，特别是降低心率的活性。
• Enzyme modulators and treatments
  申请人：Flynn L. Daniel

  公开号：US20070078121A1

  公开（公告）日：2007-04-05

  Novel compounds and methods of using those compounds for the treatment of inflammatory conditions, immunological disorders, hyperproliferative diseases, cancer, and diseases characterized by hyper-vascularization are provided. In a preferred embodiment, modulation of the activation state of kinases, including p38 kinase protein, abl kinase protein, bcr-abl kinase protein, braf kinase protein, VEGFR kinase protein, or PDGFR kinase protein, comprises the step of contacting said kinase protein with the novel compounds.

  提供了新型化合物及其使用方法，用于治疗炎症性疾病、免疫性疾病、过度增生性疾病、癌症以及以高血管化为特征的疾病。在一种优选实施方式中，调节激酶的激活状态，包括p38激酶蛋白、abl激酶蛋白、bcr-abl激酶蛋白、braf激酶蛋白、VEGFR激酶蛋白或PDGFR激酶蛋白，包括将该激酶蛋白与新型化合物接触的步骤。
• COMPOUNDS HAVING AFFINITY FOR DOPAMINE D3 RECEPTOR AND USES THEREOF"
  申请人：Bonanomi Giorgio

  公开号：US20100016287A1

  公开（公告）日：2010-01-21

  Compounds of formula (I) wherein A is a 5 or 6 membered heteroaromatic ring or a 5 or 6 membered heterocyclic ring, and which are useful for treating mental disorders such as schizophrenia are set out herein.

  本文介绍了式子（I）中A为5或6成员杂芳环或5或6成员杂环的化合物，可用于治疗精神障碍，如精神分裂症。
• ENZYME MODULATORS AND TREATMENTS
  申请人：Flynn L. Daniel

  公开号：US20080113967A1

  公开（公告）日：2008-05-15

  Novel compounds and methods of using those compounds for the treatment of inflammatory conditions, hyperproliferative diseases, cancer, and diseases characterized by hyper-vascularization are provided. In a preferred embodiment, modulation of the activation state of p38 kinase protein, abl kinase protein, ber-abl kinase protein, braf kinase protein, VEGFR kinase protein, or PDGFR kinase protein comprises the step of contacting said kinase protein with the novel compounds.

  本发明提供了新的化合物及其使用方法，用于治疗炎症状况、过度增殖性疾病、癌症和以高血管化为特征的疾病。在优选实施例中，调节p38激酶蛋白、abl激酶蛋白、ber-abl激酶蛋白、braf激酶蛋白、VEGFR激酶蛋白或PDGFR激酶蛋白的激活状态，包括将该激酶蛋白与新的化合物接触的步骤。